HLE Glascoat Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/9c2vidletl41hk2jmitm2ag1.pdf

Key Takeaways


Segment Performance & Drivers

Nilesh Ganjwala: "Very interestingly, in the last quarter, Kinam for the first time has made a breakthrough into the oil and gas industry, and we believe that that could be a path breaker for the future and could really change the entire trajectory for Kinam going forward."

Order Book & Demand Visibility

Aalap Patel: "I think regardless of the political situation in the US, I think manufacturing continues to, especially for pharma products, continues to move to the US. And when these high-end molecules move to the US, I think high-end equipment is also needed."

Margins & Profitability

Aalap Patel: "I would say quality is not the differentiator for Thaletech. I think when it comes to quality, we really believe that having great quality is a matter of hygiene. Having great quality is not a differentiator."

Strategic Initiatives

Aalap Patel: "So, it's a very, very fragmented market with something like 20, 30 different players within the Chinese glasslined equipment market, all manufacturing a wide range of equipment and also sourcing from some vendors and not always manufacturing everything themselves. I think it's a very different dynamic and it's also a very, very crowded market. So, for us to make efforts to make any inroads into China is not a priority at the moment."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Thaletec revenue run-rateRevenue in excess of INR 90 crores per quarter broadly sustainedOngoing quarters
Thaletec sustainable margins15% to 17% range for Thaletec standaloneLong-term
GLE sustainable EBITDA margins17% to 20% rangeLonger term
Filtration & drying sustainable margins16% to 18% rangeEven with current dynamics
Filtration & drying order executionOrders from current healthier book will execute and reflect in numbersNext 2–3 quarters
Debt reductionINR 35 crores done in H1; should double it for the full year (~INR 70 crores)FY25 full year
Pharma revenue mixRetained within historical 35% to 60% rangeOngoing
Pure service revenue shareOptimal level up to 10% (from ~7% currently)No date given
CapexNo capex project planned; replacement capex onlyUpcoming year
CleanMax JV paybackPayback period expected in range of ~2 years~2 years from commissioning
Kinam amalgamationNCLT application filing in process after stock exchange approvalIn process

Key Metrics

MetricQ2 FY25
Consolidated revenue₹236 cr, +5% YoY and +3.8% QoQ
EBITDA₹35.4 cr, +19% YoY and +50% QoQ
EBITDA margin15.0%
PAT~₹14 cr, +33% YoY and +166.1% QoQ
PAT margin6.1%
H1 FY25 revenue₹463 cr, +10% YoY
H1 FY25 EBITDA margin12.8%
Consolidated order book₹602 cr, +27% sequential growth as of Sep 2024
Glass-lined equipment revenue₹144 cr, +18.4% YoY
Glass-lined equipment EBITDA₹20 cr, +124% YoY
Glass-lined equipment EBITDA margin13.4%
Filtration, drying and other equipment revenue₹65 cr, -36% YoY
Filtration, drying and other equipment EBITDA margin11%
Heat transfer equipment revenue₹25 cr, +17% QoQ
Debt repaid during the quarter₹35 cr
Thaletec revenue (last two quarters)in excess of ₹90 cr per quarter
Thaletec sustainable long-term EBITDA margin15% to 17%
Glass-lined equipment sustainable long-term EBITDA margin17% to 20%
Filtration and drying sustainable long-term EBITDA margin16% to 18%
Glass-lined equipment market share (India)25% to 30%
Filtration and drying market share (domestic)50% to 60%
Pharma revenue contribution range35% to 60% of overall revenues historically
After-sales service revenue share~7% of sales, optimal level may go up to 10%
Export share from India business3% to 5%